SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma informs about newspaper publication

06 Nov 2024 Evaluate

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mankind Pharma has informed that it enclosed extracts of the consolidated unaudited financial results of the Company for the quarter and half year ended on September 30, 2024 as published in ‘Financial Express’ and ‘Jansatta’ on November 6, 2024.

The above information is a part of company’s filings submitted to BSE.

Mankind Pharma Share Price

2299.15 7.30 (0.32%)
24-Apr-2026 09:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1648.00
Dr. Reddys Lab 1323.20
Cipla 1289.70
Zydus Lifesciences 937.70
Lupin 2330.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×